Cure4 Cystic Fibrosis
- Company typePrivate
- Founded2009
- HeadquartersGreenwith, Australia
- Headcount11–50
- GTM typeB2C
- OfferingServices
Cure4 Cystic Fibrosis firmographics
Firmographics- Name
- Cure4 Cystic Fibrosis
- Legal name
- Cure4CF Foundation Limited
- Website
- https://cure4cf.org
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Cure4 Cystic Fibrosis industry classification
Industry- Product category
- Cystic Fibrosis Research Funding
- NAICS
- Grantmaking Foundations (813211), Voluntary Health Organizations (813212)
- akta.pro primary industry
- Health & Medical Research Grantmaking Foundations (BPAGAKAL)
- akta.pro secondary industries
- Research & Science Grantmaking Foundations (BPAGAKAI), Grantmaking & Philanthropic Funds (Institutional Donors) (BPADAOAB)
Keywords
Where Cure4 Cystic Fibrosis is headquartered
LocationHeadquarters
- HQ city
- Greenwith
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
Cure4 Cystic Fibrosis business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Others, Marketing or Sales, Operations, Technology or R&D
Revenue model
- Individual Donations: One-time and regular donations from individual supporters through the CF Fight Squad program, website donations, and community fundraising events.
- Bequests and Legacies: Planned giving through wills, allowing supporters to leave residual, fractional, pecuniary, or whole estate gifts to fund long-term research.
- Corporate Partnerships: Partnerships with businesses that support CF research while achieving their own corporate social responsibility objectives.
- MRFF and NHMRC Partnerships: Collaborative funding arrangements with Medical Research Future Fund and National Health and Medical Research Council for near-miss funding and partnership support.
- Community Events and Fundraising: Revenue from community-organized events including runs, swims, gala dinners, and other fundraising activities.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
Cure4 Cystic Fibrosis product offering
Product offeringCore offering
Cure4CF is a charitable foundation that funds translational cystic fibrosis research through competitive grant programs, career-development awards, and partnerships with Australian and international research institutions. Its offering consists of grant funding mechanisms (Global CF Research Integration Grant, Holckner Family CF Impact Grant, MRFF Partnership Support, NHMRC Second Chance Funding) and researcher-support awards (International Travel Award, Career Development Award, Joint Bronchiectasis Travel Award), aimed at accelerating cures and life-extending treatments for people with CF.
Product overview
Cure4 Cystic Fibrosis is Australia’s largest private funder of cystic fibrosis research, having invested over $5 million since 2009. The organization operates as a grant-making foundation offering multiple research funding programs including the Global CF Research Integration Grant (in partnership with Cystic Fibrosis Trust UK), Holckner Family CF Impact Grant, MRFF Partnership Support, and NHMRC Second Chance Funding. Additionally, it provides career development through International Travel Awards and Career Development Awards in partnership with TSANZ, and a Joint Bronchiectasis Travel Award with Lung Foundation Australia. The foundation funds a diverse portfolio of 11+ active research programs spanning gene editing, phage therapy, AI-driven disease prediction and detection, antibiotic treatments, vaccine development, and gene therapy approaches. These research initiatives are conducted by researchers across Australian universities and medical institutions, with the goal of developing life-extending and life-transforming solutions for people with cystic fibrosis.
Differentiator
Problem solved
Functional benefit
Products and services
- Global CF Research Integration Grant International research grant partnering with the Cystic Fibrosis Trust (UK) to connect Australian and UK researchers for collaborative CF projects addressing unmet needs including gastrointestinal health, infection, ageing with CF, and treatments for people who do not benefit from CFTR modulators.
- Holckner Family CF Impact Grant High-impact translational research grant supporting innovative CF projects with clear pathways to deliver tangible clinical benefits, assessed by an Independent Research Advisory Committee.
- MRFF Partnership Support Partnership support for researchers to strengthen Medical Research Future Fund applications with in-kind contributions including staff expertise, equipment, facilities, and direct research costs.
- NHMRC Second Chance Funding Near-miss funding partnership with NHMRC for Clinical Trials and Cohort Studies Scheme and Ideas Grant Scheme, supporting researchers whose applications were deemed eligible but did not receive NHMRC funding.
- International Travel Award (TSANZ partnership) AU$5,000 award in partnership with TSANZ supporting early and mid-career researchers to present CF research at international scientific conferences and build research collaborations.
- Career Development Award (TSANZ partnership) AU$15,000 award in partnership with TSANZ supporting career growth of researchers engaged in translational CF research through activities including training, travel, mentorship, childcare costs, and collaboration support.
- Joint Bronchiectasis Travel Award (Lung Foundation Australia) AU$5,000 travel award in partnership with Lung Foundation Australia for early and mid-career researchers working on bronchiectasis in CF to attend the World Bronchiectasis Conference.
- CF Fight Squad Regular Giving Program Regular giving program enabling individual donors to make recurring donations to fund Cure4CF's translational cystic fibrosis research.
- Bequest and Legacy Giving Program Planned giving program offering supporters options to leave residual, fractional, pecuniary, or whole estate gifts in their wills to fund long-term CF research, delivered in partnership with Safewill for online will writing.
- Corporate Partnership Program Partnership program enabling Australian businesses to support CF research through corporate social responsibility initiatives, with mutual benefit to the partner's community impact objectives.
Quantifiable outcome
- Over $5 million invested in CF research since 2009
- +2 more outcomes
Companies that use Cure4 Cystic Fibrosis
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles3 records
Cure4 Cystic Fibrosis technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature2 records
Cure4 Cystic Fibrosis partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- Cystic Fibrosis Trust (UK)coreInternational research partnership to accelerate CF research progress through the Global CF Research Integration Grant, connecting Australian and UK researchers. Focus areas include gastrointestinal health, infection, ageing with CF, reducing treatment burden, and therapeutic approaches for people who don't benefit from CFTR modulators. Supported by the Richardson family's generosity.
- NHMRC (National Health and Medical Research Council)coreSecond chance funding partnership in Clinical Trials and Cohort Studies Scheme as well as Ideas Grant Scheme. Researchers can indicate at submission if they'd like to be considered for near-miss funding from Cure4CF.
- MRFF (Medical Research Future Fund)minorResearchers can partner with Cure4CF to strengthen MRFF applications with in-kind and cash support. Cure4CF provides letters of support and access to staff expertise, equipment, and facilities.
- TSANZ (Thoracic Society of Australia and New Zealand)corePartnership for International Travel Awards (AU$5,000) for early and mid-career researchers to present CF research at international conferences, and Career Development Awards (AU$15,000) for translational CF researchers.
- Lung Foundation AustraliaminorJoint Bronchiectasis Travel Award ($5,000) for early and mid-career researchers working on bronchiectasis in cystic fibrosis to attend the World Bronchiectasis Conference.
- Respirion PharmaceuticalscorePartnership funding Phase 2a clinical trial for antibiotic booster RSP-1052. Cure4CF funding supports 18 Australian CF patients to participate. Respirion is a spinout from Telethon Kids Institute, partnered with Medical Research Commercialisation Fund and US Cystic Fibrosis Foundation.
- US Cystic Fibrosis FoundationminorCo-funder of Respirion Pharmaceuticals' antibiotic booster clinical trial research alongside Cure4CF.
- SafewillminorExclusive partnership offering Cure4CF supporters 50% discount on online will writing ($80) with option to include a gift to Cure4CF. Part of bequest/legacy giving program.
- CFSA (Cystic Fibrosis South Australia)minorCo-funder of Adelaide ENT Research group phage therapy research alongside Cure4CF and The Hospital Research Foundation.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
Cure4 Cystic Fibrosis competitors and assessment
Company assessmentRegional players
- Lung Foundation Australia: Australia's primary respiratory disease charity and a formal Cure4CF co-funding partner (joint Bronchiectasis Travel Award). Comparable as a donor-funded respiratory research foundation with overlapping CF-related research themes.
- Cystic Fibrosis New Zealand: New Zealand's CF-focused charity. Same disease focus and donor-led funding model, but materially smaller scale and operates in a separate (though geographically adjacent) jurisdiction.
- CFSA (Cystic Fibrosis South Australia): A domestic Australian peer with overlapping CF mission and co-funder relationship with Cure4CF (joint phage therapy research). Smaller and more care-services oriented, but the most immediate regional comparable.
- The Hospital Research Foundation: An Australian health research grantmaking charity co-funding CF phage therapy research with Cure4CF. Comparable as an Australian-domiciled, donor-funded translational research foundation, though broader in disease scope.
- Cystic Fibrosis WA: Western Australia's state-level CF charity, providing care and support services. Comparable in disease focus but smaller in research-grantmaking scope, serving a defined regional donor and patient base.
Direct peers
- Cystic Fibrosis Canada: Canada's national CF charity funding CF research and care. Comparable scope (single-disease focus, translational research grantmaking, donor-funded) and operates in a similar Western healthcare context, with overlapping research themes Cure4CF also funds.
- Cystic Fibrosis Trust: The UK's national CF charity and Cure4CF's formal Global CF Research Integration Grant partner. Directly comparable grantmaking model funding translational CF research, sharing co-funding mechanisms (Holckner Family equivalent, near-miss support) and a near-identical patient/donor mission.
Broad incumbents
- Cystic Fibrosis Foundation (US): The largest global CF research funder and Cure4CF's most significant international counterpart. Directly comparable mission (funding translational CF research toward a cure), and an active co-funder of the Respirion Phase 2a trial alongside Cure4CF — the closest institutional analog at vastly greater scale.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Cure4 Cystic Fibrosis social profiles
Digital presenceCure4 Cystic Fibrosis compliance and trust
Trust signalCompliance1 record
Cure4 Cystic Fibrosis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cure4 Cystic Fibrosis leadership team
Management profileNumber of profiles
Profiles2 records
Cure4 Cystic Fibrosis funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cure4 Cystic Fibrosis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cure4 Cystic Fibrosis
What does Cure4 Cystic Fibrosis do?
Cure4CF is a charitable foundation that funds translational cystic fibrosis research through competitive grant programs, career-development awards, and partnerships with Australian and international research institutions. Its offering consists of grant funding mechanisms (Global CF Research Integration Grant, Holckner Family CF Impact Grant, MRFF Partnership Support, NHMRC Second Chance Funding) and researcher-support awards (International Travel Award, Career Development Award, Joint Bronchiectasis Travel Award), aimed at accelerating cures and life-extending treatments for people with CF.
Is Cure4 Cystic Fibrosis a public or private company?
Cure4 Cystic Fibrosis is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Cure4 Cystic Fibrosis founded?
Cure4 Cystic Fibrosis was founded in 2009. It employs 11 to 50 people.
Where is Cure4 Cystic Fibrosis based?
Cure4 Cystic Fibrosis is headquartered in Greenwith, Australia, in the Oceania region.
How does Cure4 Cystic Fibrosis make money?
Five revenue lines are on record. Individual Donations are the primary driver. The others are bequests and Legacies, corporate Partnerships, MRFF and NHMRC Partnerships and community Events and Fundraising.
Who are Cure4 Cystic Fibrosis's main competitors?
Regional players on record are Lung Foundation Australia, Cystic Fibrosis New Zealand, CFSA (Cystic Fibrosis South Australia), The Hospital Research Foundation and Cystic Fibrosis WA. Direct peers are Cystic Fibrosis Canada and Cystic Fibrosis Trust. Cystic Fibrosis Foundation (US) is listed as a broad incumbent.
Does Cure4 Cystic Fibrosis have an API?
No public API is recorded for Cure4 Cystic Fibrosis.
What industry is Cure4 Cystic Fibrosis in?
Cure4 Cystic Fibrosis's product category is Cystic Fibrosis Research Funding. Its primary akta.pro industry code is BPAGAKAL, Health & Medical Research Grantmaking Foundations, with a secondary code of BPAGAKAI, Research & Science Grantmaking Foundations. Its NAICS code is 813211.